Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer With Symptomatic Ascites
This study is currently recruiting participants.
Verified by BioCancell Therapeutics Ltd, August 2009
First Received: January 18, 2009   Last Updated: August 30, 2009   History of Changes
Sponsored by: BioCancell Therapeutics Ltd
Information provided by: BioCancell Therapeutics Ltd
ClinicalTrials.gov Identifier: NCT00826150
  Purpose

This study is designed to assess the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy for ascites palliation of DTA-H19 administered intraperitoneally (IP) in subjects with advanced stage ovarian cancer who have evidence of symptomatic ascites


Condition Intervention Phase
Ovarian Cancer
Biological: DTA-H19
Phase I
Phase II

Study Type: Interventional
Study Design: Treatment, Open Label, Single Group Assignment, Safety/Efficacy Study
Official Title: Phase 1/2a, Dose-Escalation, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Intraperitoneal Administration of DTA-H19 in Subjects With Advanced Stage Ovarian Cancer

Resource links provided by NLM:


Further study details as provided by BioCancell Therapeutics Ltd:

Primary Outcome Measures:
  • maximum tolerated dose of DTA-H19 given intraperitoneally [ Time Frame: 8 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Quality of Life [ Time Frame: 12 Weeks ] [ Designated as safety issue: No ]
  • progression-free survival [ Time Frame: 3 months and 1 year ] [ Designated as safety issue: No ]
  • overall survival [ Time Frame: 3 months and 1 year ] [ Designated as safety issue: No ]
  • time to progression [ Time Frame: 3 months and 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 12
Study Start Date: June 2009
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Biological: DTA-H19
    Cohort #1: 60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses, maintenance for responders: 60 mg IP once per month, for 6 months. Cohort #2: 120 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses, maintenance for responders: 120 mg IP once per month, for 6 months. Cohort #3: 240 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses, maintenance for responders: 120 mg IP once per month, for 6 months. Cohort #4: 480 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses, maintenance for responders: 120 mg IP once per month, for 6 months.
Detailed Description:

This is a Phase 1/2a, open label, dose escalation, repeat dose study in 12 subjects with recurrent, platinum resistant advanced stage ovarian cancer designed to determine the tolerability, safety, quality of life, PK, and preliminary efficacy of DTA-H19 administered intraperitoneally(IP).

Primary Objective: The primary objectives of this study are:

  • To determine the maximum tolerated dose (MTD) of IP DTA-H19; and,
  • To identify any dose limiting toxicities (DLTs).

Secondary Objectives: Secondary objectives of this study are:

  • To determine the subjective clinical improvement in ascites measured by grade, frequency of paracentesis, volume of fluid collected, and absence of detectable tumor cells;
  • To determine quality of life of subjects with advanced ovarian cancer, primary peritoneal carcinoma, or tubal cancer treated with IP DTA-H19;
  • To determine the pharmacokinetics (PK) of IP DTA-H19; and,
  • To determine the overall survival distribution.
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Provide written informed consent and be at least 18 years of age.
  • Have failed at least two different primary chemotherapy regimens and have primary or secondary platinum resistant disease.
  • Have histopathologically documented epithelial ovarian carcinoma or primary peritoneal carcinoma or tubal cancer.
  • Have at least grade 1 (mild) ascites: that is observed by ultrasound.
  • Have presence of malignant cells in ascites fluid.
  • Be able to tolerate placement of IP catheter.
  • Be at least 4 weeks from last treatment to allow recovery from prior toxicity (with the exception of hormonal therapy where a 1-week wash-out period is sufficient, weekly chemotherapy where a two-week washout period is sufficient; and radiation therapy where a 3-week recovery period is sufficient.
  • Have a Karnofsky performance status score of ≥ 70%.
  • Not be of child-bearing potential.
  • Have a life expectancy of ≥ 3 months.
  • Have serum creatinine < 2.0 mg/dL, total bilirubin less than the institution's 3x upper limit of normal (ULN); AST and ALT <= 2.5 x ULN, PT, PTT, and PT/INR within normal limits, absolute neutrophil count (ANC) > 1,500 x 103 cells/mL, platelets ≥ 100,000/mL, and hemoglobin ≥ 10 mg/dL.
  • Have a biopsy specimen or an ascites fluid that is positive for H19 expression.
  • Have screening procedures completed within 6-weeks before starting treatment.
  • No significant history of cardiac disease, i.e., uncontrolled hypertension, unstable angina or congestive heart failure.
  • No prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, or in situ cervical cancer.
  • No plans to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy or any other type of therapy for treatment of cancer while on this protocol.

Exclusion Criteria:

  • Have evidence of extra abdominal disease with the exception of isolated small nodules (e.g., liver or pulmonary nodules) that are not causing symptoms.
  • Have known brain metastases.
  • Have known HIV infection.
  • Have known active viral or bacterial infections.
  • Have presence of any psychological, familiar, sociological, or geographical condition potentially hampering compliance with the study protocol or follow up schedule.
  • Have a medical condition contraindicated for laparotomy, laparoscopy, or surgery.
  • Have loculated ascites (i.e. ascites compartmentalized in different "pockets").
  • Have a history of coagulopathy.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00826150

Locations
United States, Pennsylvania
University of Pennsylvania Medical Center Recruiting
Philadelphia, Pennsylvania, United States, 19104-6142
Contact: Lana E. Kandalaft, Pharm.D, PhD     215-573-4782     lknd@mail.med.upenn.edu    
Principal Investigator: George Coukos, M.D., Ph.D.            
United States, Virginia
Massey Cancer Center Not yet recruiting
Richmond, Virginia, United States, 23298-0037
Contact: Jane W. Baggett, RN     804-628-2360     jbaggett@mcvh-vcu.edu    
Principal Investigator: Cecelia H. Boardman, M.D.            
Israel
The Edith Wolfson Medical Center Recruiting
Holon, Israel
Contact: Pnina Nir     (972)-52-8445143     pninanir@wolfson.health.gov.il    
Principal Investigator: Tally Levy, M.D.            
Hadassah University Hospital Recruiting
Jerusalem, Israel
Contact: Zoya Bezalel     (972)-2-6776725     zoyab@hadassah.org.il    
Principal Investigator: David Edelman, MD            
Meir Hospital Recruiting
Kfar Saba, Israel
Contact: Tal Naderi     09-7472213     Ta.INadiri@clalit.org.il    
Principal Investigator: Ami Fishman, MD            
Sponsors and Collaborators
BioCancell Therapeutics Ltd
Investigators
Principal Investigator: George Coukos, M.D., Ph.D. University of Pennsylvania Medical Center
Principal Investigator: Tally Levy, M.D. The Edith Wolfson Medical Center
Principal Investigator: Cecelia H. Boardman, M.D. Massey Cancer Center
Principal Investigator: David Edelman, MD Hadassah University Hospital
Principal Investigator: Ami Fishman, MD Meir Medical Center
  More Information

No publications provided

Responsible Party: BioCancell Therapeutics Ltd. ( Patricia Ohana, Ph.D. )
Study ID Numbers: BC-08-01
Study First Received: January 18, 2009
Last Updated: August 30, 2009
ClinicalTrials.gov Identifier: NCT00826150     History of Changes
Health Authority: United States: Food and Drug Administration;   Israel: Ministry of Health

Keywords provided by BioCancell Therapeutics Ltd:
ovarian cancer
H19 gene
plasmid

Study placed in the following topic categories:
Genital Diseases, Female
Ovarian Neoplasms
Gonadal Disorders
Ascites
Genital Neoplasms, Female
Ovarian Cancer
Endocrine System Diseases
Urogenital Neoplasms
Endocrinopathy
Ovarian Diseases
Endocrine Gland Neoplasms

Additional relevant MeSH terms:
Genital Diseases, Female
Neoplasms
Neoplasms by Site
Ovarian Neoplasms
Gonadal Disorders
Genital Neoplasms, Female
Endocrine System Diseases
Urogenital Neoplasms
Ovarian Diseases
Adnexal Diseases
Endocrine Gland Neoplasms

ClinicalTrials.gov processed this record on September 11, 2009